Oruka Therapeutics Inc. Common Stock vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $37.9 (market cap $29.26M). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 177× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 64 Days on average.
| ORKA | QDTY | |
|---|---|---|
Market Cap | $5.18B | $29.26M |
Volume | 490,798 | 13,576 |
Sector | Health | Income / Options Overlay |
52-Week High | $113.08 | $46.71 |
52-Week Low | $26.19 | $36.57 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $4.31B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QDTY trades at $38.94, down 0.36% with bearish technical signals from moving averages. The ETF maintains a consistent weekly dividend distribution strategy, with recent payments ranging from $0.19 to $0.30 per share. Technical indicators show mixed signals with RSI in neutral territory while ADX suggests weakening trend strength. The stock faces resistance at $40 with support clustered around $39.
The outlook remains cautious given bearish technical momentum and concentrated support levels. Dividend consistency provides income appeal, but technical weakness and tight trading range near current levels suggest limited near-term upside potential. Key risks include market volatility impact on covered call strategies and dependency on Nasdaq 100 performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →